BPC-157 vs TB-500
Compare the research, key figures and safety notes.
How they differ
The two most popular recovery peptides, and they leave the body at very different speeds. BPC-157 is a short peptide that's gone within a few hours; TB-500 is a piece of a larger protein and lingers for days. Neither has been tested in a human dosing trial — the evidence is animal repair studies — so the amounts people quote come from the community, not from research.
Side by side
| Measure | BPC-157 | TB-500 |
|---|---|---|
| Category | Recovery | Recovery |
| Evidence | C · Animal or lab only | C · Animal or lab only |
| Route | Route not established | Route not established |
| Half-life | 4 h | 60 h |
| Typical vial | 5 / 10 mg | 5 / 10 mg |
| Research amount | 200–500 mcg | 2–5 mg |
| Common schedule | Every day | 2x per week |
| Cycle / break | 4–6 / 2–4 | 4–6 loading / 2–4 |
| Studied for | Repair and recovery | Repair and recovery |
These amounts and schedules are figures discussed in research and community reports, shared for learning — not a recommendation and not medical advice. A step-by-step dosing schedule exists only where a human trial backs it; the evidence tier tells you which.
Decay curves, overlaid
Each line is scaled to that compound's own first dose, so the chart shows how each one builds up over time — not how the compounds' doses compare to one another, which these different molecules share no common unit for.
How they combine
Educational reference on commonly-discussed combinations, not medical advice. Combining compounds can change how each behaves — read this as a prompt to research, not a clearance.